These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8031871)

  • 1. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method.
    Li M; Meares CF; Zhong GR; Miers L; Xiong CY; DeNardo SJ
    Bioconjug Chem; 1994; 5(2):101-4. PubMed ID: 8031871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prelabeling of chimeric monoclonal antibody L6 with 90yttrium- and 111indium-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA) chelates for radioimmunodiagnosis and therapy.
    Li M; Meares CF; Salako Q; Kukis DL; Zhong GR; Miers L; DeNardo SJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5726s-5728s. PubMed ID: 7493335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
    Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
    DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
    J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates.
    Gansow OA
    Int J Rad Appl Instrum B; 1991; 18(4):369-81. PubMed ID: 1864725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
    Lewis MR; Raubitschek A; Shively JE
    Bioconjug Chem; 1994; 5(6):565-76. PubMed ID: 7873659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.
    Malmberg J; Perols A; Varasteh Z; Altai M; Braun A; Sandström M; Garske U; Tolmachev V; Orlova A; Karlström AE
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):481-92. PubMed ID: 22322933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
    Deshpande SV; DeNardo SJ; Kukis DL; Moi MK; McCall MJ; DeNardo GL; Meares CF
    J Nucl Med; 1990 Apr; 31(4):473-9. PubMed ID: 2324823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
    Pnwar P; Iznaga-Escobar N; Mishra P; Srivastava V; Sharma RK; Chandra R; Mishra AK
    Cancer Biol Ther; 2005 Aug; 4(8):854-60. PubMed ID: 16082184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use.
    Hainsworth JE; Mather SJ
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1348. PubMed ID: 16142470
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
    Kukis DL; DeNardo SJ; DeNardo GL; O'Donnell RT; Meares CF
    J Nucl Med; 1998 Dec; 39(12):2105-10. PubMed ID: 9867151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions.
    Lewis MR; Shively JE
    Bioconjug Chem; 1998; 9(1):72-86. PubMed ID: 9460549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
    Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes.
    Sosabowski JK; Mather SJ
    Nat Protoc; 2006; 1(2):972-6. PubMed ID: 17406332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy.
    Kosmas C; Snook D; Gooden CS; Courtenay-Luck NS; McCall MJ; Meares CF; Epenetos AA
    Cancer Res; 1992 Feb; 52(4):904-11. PubMed ID: 1737353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions.
    Li L; Tsai SW; Anderson AL; Keire DA; Raubitschek AA; Shively JE
    Bioconjug Chem; 2002; 13(1):110-5. PubMed ID: 11792185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
    Camera L; Kinuya S; Garmestani K; Brechbiel MW; Wu C; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    Eur J Nucl Med; 1994 Jul; 21(7):640-6. PubMed ID: 7957350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid.
    Smith-Jones PM; Fridrich R; Kaden TA; Novak-Hofer I; Siebold K; Tschudin D; Maecke HR
    Bioconjug Chem; 1991; 2(6):415-21. PubMed ID: 1805938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.